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Striking results reported by Okuno et al. (2012) in the July issue of Nature Medicine show that the ataxia
telangiectasia mutated (ATM) kinase counteracts excessive oxygen radical production in immature angio-
genic blood vessels. Its deletion results in activation of the mitogen-activated protein kinase p38a and
arrest of pathological angiogenesis.Angiogenesis is implicated in the patho-
genesis of a variety of common human
diseases, but clinical success in angio-
genesis control has so far only been
achieved in age-relatedmacular degener-
ation by use of antibodies that block
vascular endothelial growth factor
(VEGF). These antibodies have also
increased the progression-free survival
of patients within a select group of
neoplasms but overall survival in only
few tumor types (Crawford and Ferrara,
2009). However, the selective targeting
of pathological angiogenesis as opposed
to angiogenesis in developmental or
regenerative processes such as wound
healing has not been possible. Okuno
et al. (2012) now report an interesting
target, the ataxia telangiectasia mutated
(ATM) pathway, that appears to be
necessary for angiogenesis triggered
by tissue hypoxia in the eye and in
malignant tumors but not during normal
vascularization.
The ATM kinase is known to regulate
the cellular DNA damage response
(DDR) and to act as a redox sensor that
controls the levels of reactive oxygen
species. ATM also regulates mitochon-
drial function and cellular metabolism
via the p53 tumor suppressor, AMP-
activated protein kinase (AMPK), mam-
malian target of rapamycin (mTOR), and
hypoxia-inducible factor 1 (HIF1) (Ditch
and Paull, 2012). Interestingly, patients
with ataxia telangiectasia and aged
Atm-deficient mice exhibit blood vessel
abnormalities, such as dilated blood
vessels and vascular leakiness in the
retina.
To study the role of ATM in pathological
angiogenesis, Okuno et al. used a mouse
model of oxygen-induced retinopathy,
commonly employed in studiesmimicking
retinopathy of prematurity and prolifera-tive diabetic retinopathy, as well as in
preclinical evaluation of antiangiogenic
compounds. ATM was activated in retinal
neovascular tufts, which are similar
to poorly perfused and unstable tumor
vessels. The tufts undergo repeated
cycles of hypoxia and reoxygenation and
are generated in response to angiogenic
factors secreted by surrounding hypoxic
cells.
It is known that hypoxia by itself is
not sufficient for generating the full
neovascular response unless hypoxia
is sensed by mitochondria, the largest
cellular oxygen consumers. The most
likely angiogenic signal generated by
the poorly functioning mitochondria in
hypoxic cells is a burst of reactive oxygen
species (ROS). With elegant experiments
involving genetic mouse models and
inhibitor compounds, Okuno et al. show
that ROS production in the mouse model
results in activation of the ATM kinase in
the abnormal neovascular tufts, but not
in the tip cells of normal angiogenic vessel
sprouts. Furthermore, ATM activation
was inhibited by administration of an anti-
oxidant, whereas deletion of theAtm gene
in the mice or only in their endothelial cells
decreased ROS-degrading enzymes, re-
sulting in excessive ROS and activation
of the mitogen-activated protein kinase
p38a, which led to arrest of pathological
angiogenesis. Thus, the role of ATM is to
halt the extent of the ROS signal, too
much ROS being deleterious for the
neovascular process. Okuno et al. further-
more show that ATM deficiency counter-
acts tumor angiogenesis and increases
the antiangiogenic efficacy of a vascular
endothelial growth factor (Vegf) receptor
2 (Vegfr2) tyrosine kinase inhibitor.
Although the Atm-deleted mice had
almost no pathological angiogenesis,
they showed enhanced revascularizationCell Metabolism 16, Sof poorly perfused regions. In contrast,
Vegf or Vegfr2 inhibitors suppress both
the formation of neovascular tufts and
the recovery of normal vessels in the
same model (Kubota et al., 2009). In this
regard, the findings by Okuno et al. are
particularly important, because the
ATM mechanism differentiates between
developmental and pathological angio-
genesis. Furthermore, the discovery of
Okuno et al. links a metabolic target with
the angiogenesis process; ATM has also
gathered increasing attention as a target
in metabolic syndrome (Schneider et al.,
2006).
Previous landmark studies by Suda
and coworkers have indicated that ATM
regulation of ROS is critical in the regu-
lation of hematopoietic stem cell (HSC)
quiescence and that an antioxidant or
p38 inhibitor protects HSCs against loss
of self-renewal capacity, extending the
life span of HSCs (Ito et al., 2006). This
work indicated that the p38a activation
by ROS leads to increased expression
of several cell-cycle inhibitors, a likely
reason also for the arrest of neovascular
growth in the present model. Although
DDR signaling downstream of ATM has
been reported to contribute to the activa-
tion of the p53 tumor suppressor, down-
stream cell-cycle inhibitors, and cellular
senescence in the vascular endothelium
(Zhan et al., 2010), in the present study
of Okuno et al., the function of ATM in
angiogenesis was DDR independent.
These results suggest that possible
therapeutic outcomes of ROS and p38
inhibitors would be favorable or delete-
rious, depending on the tissue context.
Additional considerations are necessary
when contemplating the therapeutic
targeting of pathological angiogenesis
at the level of ATM. For example, by
controlling the DDR, ATM acts as one ofeptember 5, 2012 ª2012 Elsevier Inc. 287
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Previewsthe upstream regulators of the p53 tumor
suppressor, the guardian of the genome
against DNA mutations. Second, the
titration of potential therapeutic drugs
would be difficult, as the response to the
ROS burst is biphasic: some ROS is
necessary for the cellular responses to
hypoxia, including (tumor) angiogenesis,
while too much is deleterious for the
angiogenic endothelium, as seen in the
case of ATM deficiency.
The regulation of endothelial oxygen
sensing and metabolism is certainly
an area where additional angiogenesis
inhibitors could be explored, and the
paper by Okuno et al. reveals one striking
example of success with this approach.
Current angiogenesis inhibitors provoke
at least transient hypoxia before vessel288 Cell Metabolism 16, September 5, 2012 ªnormalization, and inhibition of the
pathway identified by Okuno et al. could
be particularly effective in this context.
The immature, growing endothelium that
is subject to angiogenic factor stimulation
seems to be particularly sensitive to
ROS generation during hypoxia, and the
selective effect of the ATM pathway
would thus increase the targeting speci-
ficity. Undoubtedly, the importance of
the ROS-ATM-p38 pathway should also
be further explored in other vascular
disease processes such as atheroscle-
rosis and hypertension.REFERENCES
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The cellular origins and molecular determinants of brown adipose tissue (BAT) are the focus of renewed
attention. Serendipitous studies examining hematopoiesis in human pluripotent stem cell cultures (Nishio
et al., 2012, in this issue of Cell Metabolism) now identify cytokines capable of inducing BAT differentiation
from these human stem cells and suggest a link between BAT and blood cells.Brown adipose tissue (BAT) has the
unique ability to act as a nonshivering
thermogenic organ. When rodents are
exposed to cold environments or treated
with b3-adrenergic agonists, their BAT
increases in volume and undergoesmeta-
bolic changes. This is accompanied by
increased numbers of mitochondria,
giving the tissue its brown color, and the
induced expression of uncoupling protein
1 (UCP1). UCP1 is found in mitochondria,
where it is responsible for short circuiting
the mitochondrial proton gradient, there-
by converting energy directly into heat.
For small animals with large surface area
to volume ratios and for newborn humans,
BAT protects critical organs (heart,
kidney, aorta) against cold environments
by maintaining their core body tempera-
ture. Until recently, many investigatorsthought that BAT disappeared during
human development; however, sophisti-
cated radiological imaging technologies
have uncovered the persistence of BAT
in adult human subjects, where it has
been associated with a lean, rather than
obese, phenotype. Consequently, uncov-
ering a mechanism to prevent adipose
tissue progenitor cells from selecting
a white for a brown adipocyte differentia-
tion pathway has been a ‘‘holy grail’’ for
some obesity researchers. The pioneering
discovery of the brown adipocyte-selec-
tive zinc finger transcription factor,
PRDM16, was a critical milestone in this
field (Seale et al., 2007). Seale and
colleagues demonstrated that transduc-
tion of PRDM16 into white adipocyte
progenitors led to their conversion into
thermogenic brown adipocytes (Sealeet al., 2007). A subset of white adipose
cells, known both as ‘‘beige’’ or ‘‘brite’’
cells, undergo thermogenic differentiation
upon exposure to prostaglandins (Ishiba-
shi and Seale, 2010; Vegiopoulos et al.,
2010). Likewise, treatment of murine
adipocyte progenitor cells with bone
morphogenetic protein 7 (BMP7) has
been found to induce PRDM16 expres-
sion and conversion into brown adipo-
cytes (Tseng et al., 2008); however, this
protocol has displayed variable efficiency
when performed with human white adipo-
cyte progenitors (Schulz et al., 2011).
Thus, the mechanism underlying human
brown adipogenesis may not be identical
to that of the murine system. Since
pharmacological induction of human
BAT has promise to prevent or treat
obesity, there is a need for reliable and
